Navigation Links
Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
Date:3/4/2009

100% Technical Success, No Peri-procedural Complications Reported With Coronary Device

DOYLESTOWN, Pa., March 4 /PRNewswire/ -- Prescient Medical, Inc. reached a crucial milestone in February by completing the enrollment of 30 patients in the first phase of its first-in-human clinical trial for the vProtect(TM) Luminal Shield, conducted at the Corbic Research Institute in Colombia. The Shield successfully crossed all target lesions and was safely implanted in all 30 patients, with a technical success rate of 100%. No procedural or in-hospital complications were reported for any of the patients. The patients enrolled in the study had non-calcified lesions in coronary arteries, lesions that would normally be treated with traditional balloon-expandable stents.

No major adverse coronary events (MACE) were reported at 30 days post-implant in the 28 patients who had reached that milestone. Nine-month angiographic follow-up was reported for 2 initial patients; there was no evidence of significant neointimal growth in these patients. "We are very pleased with the performance of the Shield in this preliminary study. We have achieved an excellent technical result, and soon we will know more about clinical outcomes with the Shield," said co-principal investigator Juan A. Delgado, MD of Corbic Research Institute.

Prescient Medical has also broken new ground with a study evaluating use of the vProtect(TM) Luminal Shield in non-obstructive "vulnerable plaque" lesions that may rupture and cause acute myocardial infarction. According to Dr. Delgado, "The self-expanding Shield is designed to deploy with less injury to the artery, which should reduce neointimal overgrowth compared with currently marketed bare metal stents. We think these properties make the Shield a promising treatment to stabilize vulnerable plaque and prevent major events like heart attacks."

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at www.prescientmedical.com or call +1-866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
2. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
3. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
4. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
5. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
6. Foreign Medical Devices are in High Demand in Russia
7. Oridion Announces Significant Medical Studies Presented at STA
8. AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
9. Impact Medical Solutions Announces Appointment of New Director and Corporate Update
10. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
11. ProUroCare Medical Inc. Announces Pricing of Equity Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- The Board of Directors of Nordic Nanovector ... including the complete 2016 Annual Accounts with notes. The report ... website in the section Investor Relations/Reports and presentations/Annual Reports. ... For further ... Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
(Date:3/23/2017)... Research and Markets has announced the addition ... Replacement Procedure By Technique, Repair Procedure By Technique, By Region, By ... ... forecasted to grow at a CAGR of 13.35% during 2016-2021 ... rising aging population, growth in population with heart disease and rising ...
(Date:3/23/2017)... 2017 As a result of diagnostic ... prevalence of allergic diseases, cutting edge developments in ... the ways in which pharmaceutical and biotech companies ... to be both a high quality meeting and ... groups, immunologists, research scholars and doctors. The event ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian ... Bible teacher residing in North Carolina with his wife, Anna Marie. He and his ... six grandchildren. David is also the author of “Shadow and Substance.” , “Love, the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... In 2016 ... now estimates that there could be four million Zika-related cases in the Americas within ... with numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, ...
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and businesses of the Norwalk and Vermillion areas, celebrates the newest charity ... is a nonprofit, community-based substance abuse prevention and peer recovery support organization ...
Breaking Medicine News(10 mins):